Millions of people around the world are using GLP-1 medications like Ozempic and Wegovy to lose weight and manage Type 2 diabetes. These drugs have been hailed as a medical breakthrough, with clinical trial results showing average weight loss of 15% or more. Yet for a significant number of patients, the results never arrive.
They follow the protocol. They inject on schedule. They wait weeks, then months. The scale barely moves. Blood sugar stays stubborn. And they’re left wondering: why isn’t this working for me?
New research from Stanford Medicine may finally have an answer. It’s called GLP-1 resistance, and it affects roughly 1 in 10 people.
What Is GLP-1 Resistance?
GLP-1, or glucagon-like peptide-1, is a hormone your body produces naturally in the gut. It plays a central role in regulating blood sugar, slowing digestion, and signaling fullness to the brain. If you have ever felt satisfied after a balanced meal, GLP-1 was part of that process. In fact, the gut-brain connection is far more powerful than most people realize, and GLP-1 sits right at the center of it.
GLP-1 receptor agonist medications, such as semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound), work by mimicking this hormone. They bind to GLP-1 receptors in the body and amplify its effects, resulting in reduced appetite, improved blood sugar control, and significant weight loss for many patients.
GLP-1 resistance is a newly defined phenomenon where a person’s body produces normal or even elevated levels of GLP-1, but the hormone does not function with full biological effectiveness. In simpler terms, the signal is there, but the body cannot hear it properly.
This is not the same as “not trying hard enough.” It is not a willpower issue. GLP-1 resistance is a measurable, genetically influenced biological condition, and it can directly reduce how well drugs like Ozempic, Wegovy, Mounjaro, or Zepbound work.
The Science Behind It: PAM Gene Variants Explained
A landmark study published in Genome Medicine on April 10, 2026, by researchers at Stanford Medicine and collaborators at ETH Zurich, has identified the first clear genetic mechanism behind GLP-1 resistance.
The study focused on a gene called PAM, which stands for peptidyl-glycine alpha-amidating monooxygenase. PAM encodes the only enzyme in the human body capable of a chemical process called amidation. Amidation is what activates certain peptide hormones, including GLP-1, by increasing their potency and extending their lifespan in the bloodstream.
When PAM functions normally, GLP-1 is activated efficiently and does its job. But roughly 10% of the general population carries specific variants in the PAM gene, most notably p.S539W and p.D563G, that impair this activation process.
Here is the paradox that makes GLP-1 resistance so difficult to detect: people with these PAM variants actually have higher circulating levels of GLP-1 than the average person. But despite those elevated levels, the hormone is approximately 18% less biologically effective. The GLP-1 is present in the blood, but it has not been properly activated, so it cannot send the right signals to the body.
The Stanford researchers analyzed data from a meta-analysis of three clinical trials involving 1,119 participants. They found that people carrying the p.S539W variant reached their target HbA1c levels only 11.5% of the time after six months of GLP-1 treatment, compared to 25% for non-carriers. That is a striking difference in treatment outcome.
Importantly, the resistance appears to be specific to GLP-1 medications. Carriers of PAM variants responded normally to other diabetes drugs including metformin, sulfonylureas, and DPP-4 inhibitors, which suggests the issue is not general drug resistance but a targeted problem with how GLP-1 is processed in the body.
Professor Anna Gloyn, a senior author of the study and professor of pediatrics and genetics at Stanford Medicine, noted that her team first observed GLP-1 resistance nearly a decade ago, well before these medications became global weight-loss phenomena. The exact mechanism by which PAM variants cause resistance remains under investigation, but the clinical evidence is strong.
This research has important implications for anyone managing Type 2 diabetes or using diabetes medications. It suggests that the future of metabolic treatment will be increasingly personalized.
Signs That Ozempic or Wegovy May Not Be Working for You
Not every slow response to a GLP-1 medication means you have GLP-1 resistance. These drugs work gradually, and it is normal for results to build over the first several weeks as doses are titrated upward.
However, certain patterns may signal that you are among those who do not respond as expected. If you have been on a GLP-1 receptor agonist at a therapeutic dose for at least three to four months, consider whether these situations apply to you.
Minimal or no weight change is the most visible indicator. While individual results vary, most clinical trials show meaningful weight loss by the three-month mark at therapeutic doses. If you have seen less than 3% body weight loss after four months, your response may be significantly below average.
Persistent appetite and cravings are another sign. One of the most notable effects of GLP-1 drugs is appetite suppression. Many patients report feeling dramatically less hungry, especially a reduction in “food noise.” If your hunger levels and snacking habits have not changed, the medication may not be engaging your GLP-1 receptors effectively. This is particularly relevant for people who have noticed increased snacking patterns that don’t resolve even with medication.
Blood sugar that remains poorly controlled despite consistent use and appropriate dosing is a clinical red flag. If HbA1c levels are not improving after three to six months, your endocrinologist should evaluate whether the current medication is the right fit.
Gastrointestinal side effects without benefits can be especially frustrating. Many patients experience nausea, constipation, or digestive discomfort as common side effects of GLP-1 drugs. If you are experiencing those side effects but not seeing the weight loss or blood sugar improvements that typically accompany them, it may indicate that the drug is reaching your system but not producing the expected metabolic response.
None of these signs alone confirm GLP-1 resistance, but a combination of them warrants a conversation with your healthcare provider about next steps, including the possibility of pharmacogenomic testing.
GLP-1 Medications Compared: Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound
Understanding the differences between the major GLP-1 and GLP-1/GIP medications can help you and your doctor determine whether switching drugs might improve your outcomes. Here is how the four most widely prescribed options compare as of June 2026.
Medication Comparison Table
| Feature | Ozempic | Wegovy | Mounjaro | Zepbound |
| Active Ingredient | Semaglutide | Semaglutide | Tirzepatide | Tirzepatide |
| Drug Class | GLP-1 receptor agonist | GLP-1 receptor agonist | Dual GLP-1/GIP agonist | Dual GLP-1/GIP agonist |
| FDA-Approved For | Type 2 diabetes | Chronic weight management | Type 2 diabetes | Chronic weight management |
| Max Dose | 2 mg/week | 2.4 mg/week | 15 mg/week | 15 mg/week |
| Average Weight Loss (Trials) | ~8–14% | ~15% (STEP trials) | ~15–20% (SURPASS trials) | ~21% (SURMOUNT trials) |
| Administration | Weekly injection | Weekly injection | Weekly injection | Weekly injection |
| Cardiovascular Benefit Proven | Yes (SELECT trial) | Yes (SELECT trial) | Under study (SURPASS-CVOT) | Under study |
| Addresses GIP Pathway | No | No | Yes | Yes |
The SURMOUNT-5 trial, published in JAMA Internal Medicine, was the first direct head-to-head comparison of tirzepatide versus semaglutide. The results showed that tirzepatide (the active ingredient in Mounjaro and Zepbound) produced significantly greater weight loss, with a difference of approximately 6.5 percentage points over 72 weeks. For a 220-pound patient, that translates to roughly 44 pounds lost with tirzepatide compared to 30 pounds with semaglutide.
For patients who are not responding well to semaglutide-based drugs, switching to a dual-agonist medication that also targets the GIP receptor may provide a meaningful improvement in outcomes. This is a conversation worth having with your prescribing physician, especially in light of the new GLP-1 resistance research.
What to Do If You Are a GLP-1 Non-Responder
If you suspect you may have GLP-1 resistance or are simply not seeing the results you expected, there are several evidence-based paths forward. None of these should be pursued without medical guidance, but they represent the current state of what science and clinical practice offer.
1. Talk to Your Doctor About Dose Optimization
Before concluding that a drug is not working, ensure you have reached the maximum therapeutic dose and maintained it long enough. Many patients are undertreated because they remain on lower titration doses due to side effects. Your doctor may adjust the schedule or manage side effects to help you tolerate a full dose.
2. Ask About Pharmacogenomic Testing
Genetic testing for PAM variants is not yet standard clinical practice, but it is becoming increasingly accessible as pharmacogenomic panels expand. Several major health systems in the United States already offer these panels, and researchers expect PAM variants to be incorporated into precision diabetes testing in the coming years. If you have a family history of poor response to GLP-1 medications, this testing may be especially valuable.
3. Consider Switching Drug Classes
If semaglutide (Ozempic or Wegovy) is not working, switching to tirzepatide (Mounjaro or Zepbound) targets an additional hormonal pathway (GIP) that is not affected by PAM-related GLP-1 resistance. The Stanford study found that GLP-1 resistance is specific to the GLP-1 pathway, so drugs that act on multiple receptors may partially bypass the issue.
4. Monitor Next-Generation Drugs
Retatrutide, an investigational triple agonist developed by Eli Lilly, targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials (the TRIUMPH program) have shown average weight loss of approximately 28.7% at the highest doses, substantially exceeding results from any currently approved medication. As of June 2026, retatrutide has not yet received FDA approval and remains in advanced clinical trials, with a potential New Drug Application expected in late 2026 or early 2027. For GLP-1 non-responders, triple agonists represent one of the most promising future options because they engage metabolic pathways beyond GLP-1 alone.
5. Strengthen Lifestyle Foundations
Medication works best in combination with sustainable lifestyle changes. Research consistently shows that diet, movement, sleep, and stress management amplify the effects of GLP-1 drugs, and they become even more critical if the medication alone is not delivering full results.
A plant-based diet rich in fiber and whole foods has been shown to support gut hormone function. Intermittent fasting is another strategy many patients pair with GLP-1 therapy to enhance metabolic outcomes. And addressing the psychological side of weight management matters too, because self-sabotage patterns can undermine even the most effective medical treatments.
The Future of Personalized Weight Loss Medicine
The discovery of GLP-1 resistance marks a turning point in how we think about obesity treatment. For years, the assumption was straightforward: prescribe the drug, the patient loses weight. When it did not work, the default explanation was often poor compliance, inadequate diet, or insufficient exercise.
The Stanford PAM gene research dismantles that assumption. It provides the first hard genetic evidence that some people’s bodies are biologically less capable of responding to an entire class of medications, and it opens the door to a future where treatment is tailored to a patient’s genetic profile before a single dose is administered.
The American Diabetes Association’s 2026 Standards of Care already acknowledge that individual patient responses to GLP-1 therapy vary substantially. What the Stanford study adds is a molecular explanation for a significant portion of that variation.
Precision medicine in the weight loss space is no longer theoretical. Within the next few years, it is reasonable to expect that pharmacogenomic testing will become a routine step before prescribing GLP-1 medications, much as genetic testing already guides treatment decisions in oncology. Patients who carry PAM variants could be steered toward dual or triple agonist therapies from the start, saving months of ineffective treatment and the emotional toll of feeling like a failure on a drug that was never going to work for them.
This is the future of metabolic medicine: not one drug for everyone, but the right drug for the right person.
Frequently Asked Questions
What is GLP-1 resistance?
GLP-1 resistance is a condition in which the body produces normal or elevated levels of the hormone GLP-1, but the hormone is less biologically effective than expected. Research published in Genome Medicine in April 2026 by Stanford Medicine identified variants in the PAM gene, carried by approximately 10% of the population, as a key cause. People with GLP-1 resistance may not respond as well to medications like Ozempic, Wegovy, Mounjaro, or Zepbound.
Why is Ozempic not working for me?
There are several reasons Ozempic may not produce expected results. You may not yet be at a therapeutic dose, your diet and activity levels may be limiting outcomes, or you could be among the roughly 10% of people with genetic GLP-1 resistance. If you have been on a full dose for three to four months without meaningful weight loss or blood sugar improvement, consult your doctor about alternative treatments or pharmacogenomic testing.
Can genetics affect how GLP-1 drugs work?
Yes. A 2026 Stanford Medicine study found that specific variants in the PAM gene reduce the biological effectiveness of GLP-1 by approximately 18%, even when circulating hormone levels are higher than average. This genetic factor can significantly reduce the effectiveness of GLP-1 receptor agonist medications. Carriers responded normally to other diabetes drugs, indicating the resistance is specific to the GLP-1 pathway.
What is the PAM gene and how does it affect GLP-1 medications?
The PAM gene encodes an enzyme called peptidyl-glycine alpha-amidating monooxygenase, which is the only enzyme in the human body capable of a process called amidation. Amidation activates peptide hormones including GLP-1 by increasing their potency. When PAM gene variants such as p.S539W or p.D563G impair this process, GLP-1 circulates in higher amounts but with reduced effectiveness, leading to poorer response to GLP-1 medications.
What should I do if I am an Ozempic non-responder?
Start by discussing your response with your healthcare provider to confirm you have been on an adequate dose for a sufficient period. Ask about pharmacogenomic testing for PAM variants. Consider whether switching from a GLP-1-only drug (like Ozempic or Wegovy) to a dual-agonist drug (like Mounjaro or Zepbound) could help, as these target the GIP pathway in addition to GLP-1. Strengthen lifestyle factors including diet, exercise, and sleep. Watch for next-generation drugs like retatrutide, which target three receptor pathways.
Is there a test for GLP-1 resistance?
Genetic testing for PAM variants is not yet included in standard clinical panels, but pharmacogenomic testing is becoming more widely available through major health systems. Researchers expect PAM variants to be incorporated into precision diabetes and obesity medicine testing in the near future. Ask your doctor whether pharmacogenomic panels are available at your healthcare facility.
How is Mounjaro different from Ozempic?
Ozempic contains semaglutide, a GLP-1 receptor agonist that targets one hormonal pathway. Mounjaro contains tirzepatide, a dual GLP-1/GIP receptor agonist that targets two hormonal pathways. In the head-to-head SURMOUNT-5 trial, tirzepatide produced significantly greater weight loss than semaglutide, with a difference of approximately 6.5 percentage points over 72 weeks. For patients with GLP-1 resistance, dual-agonist medications may partially bypass the GLP-1-specific resistance caused by PAM gene variants.
What is retatrutide?
Retatrutide is an investigational triple agonist drug developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials have shown average weight loss of approximately 28.7% at the highest doses, exceeding any currently approved medication. As of June 2026, retatrutide is not FDA-approved and remains in advanced clinical trials. It represents one of the most promising future treatments for patients who do not respond adequately to current GLP-1 medications.
Sources
- Umapathysivam, M., Araldi, E., et al. (2026). Genetic variants in PAM modify response to GLP-1 receptor agonists. Genome Medicine, April 10, 2026. DOI: 10.1186/s13073-026-01630-0
- Stanford Medicine News. “One in 10 people may have resistance to GLP-1 diabetes drugs.” Stanford Report, April 10, 2026.
- Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
- SURMOUNT-5 Trial Results. JAMA Internal Medicine. Tirzepatide vs. semaglutide head-to-head comparison.
- Lincoff, A.M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine.
- Eli Lilly (May 21, 2026). Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. PR Newswire.
- American Diabetes Association. 2026 Standards of Care in Diabetes.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. GLP-1 medications require a prescription and ongoing medical supervision.
